Triple Negative Breast Cancer Clinical Trials

68 studies are recruiting for triple negative breast cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

   The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California

   Locations

   13 in total

   Run by

   Pfizer

   See if you can join NCT07318805 on ClinicalTrials.gov

2. Sacituzumab Govitecan In TNBC

   This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   5 in total

   Run by

   Massachusetts General Hospital

   See if you can join NCT04230109 on ClinicalTrials.gov

3. Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

   This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT07064018 on ClinicalTrials.gov

4. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

   A Study of Emi-Le in Participants with Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

   Locations

   26 in total

   Run by

   Day One Biopharmaceuticals, Inc.

   See if you can join NCT05377996 on ClinicalTrials.gov

5. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center /ID# 276272, Duarte, California

   Locations

   48 in total

   Run by

   AbbVie

   See if you can join NCT05005403 on ClinicalTrials.gov

6. A Study of LY4175408 in Participants With Advanced Cancer

   The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford Medicine Cancer Center, Stanford, California

   Locations

   27 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07046923 on ClinicalTrials.gov

7. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

   This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at HealthONE, Denver, Colorado

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07503808 on ClinicalTrials.gov

8. MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

   This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible sub…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   2 in total

   Run by

   Memgen, Inc.

   See if you can join NCT05076760 on ClinicalTrials.gov

9. ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

   This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are n…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Laura Huppert, MD, BA

   See if you can join NCT06224673 on ClinicalTrials.gov

10. A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

    This phase Ib trial tests the safety, side effects and best dose of anti-HLA-A2/NY-ESO-1 T-cell receptor (TCR)-transduced autologous T lymphocytes (A2-ESO-1 TCR-T cells) in treating patients with NY-ESO-1 overexpression positive triple negative breast cancer (TNBC) that has come back after a period…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC / Norris Comprehensive Cancer Center, Los Angeles, California

    Run by

    University of Southern California

    See if you can join NCT05989828 on ClinicalTrials.gov

11. NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

    This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligible for anthracycline-based therapy due to underlying cardia…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Medical University of South Carolina, Charleston, South Carolina

    Run by

    Medical University of South Carolina

    See if you can join NCT06845319 on ClinicalTrials.gov

12. Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

    The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacit…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California San Francisco, San Francisco, California

    Locations

    7 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04434040 on ClinicalTrials.gov

13. ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

    This translational biomarker study will collect blood in patients Stage I triple negative breast cancer at diagnosis prior to either neoadjuvant treatment or surgery and then during treatment.

    Stage

    Not phased

    Ages

    18 and older

    Site

    UPMC Hillman Cancer, Pittsburgh, Pennsylvania

    Run by

    University of Pittsburgh

    See if you can join NCT07332975 on ClinicalTrials.gov

14. Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

    This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Stamford Hospital, Stamford, Connecticut

    Locations

    15 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04468061 on ClinicalTrials.gov

15. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Arkansas Medical School, Little Rock, Arkansas

    Locations

    19 in total

    Run by

    NiKang Therapeutics, Inc.

    See if you can join NCT06586957 on ClinicalTrials.gov

16. A Study of Tetrathiomolybdate (TM) Plus Capecitabine

    There are two parts to this study. It is a phase 1b followed by a randomized phase 2 study to assess whether adding 3 years of adjuvant tetrathiomolybdate (TM) to standard 6 months treatment of adjuvant capecitabine and pembrolizumab in high risk for relapse triple negative breast cancer. In the ph…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

    Locations

    3 in total

    Run by

    Dartmouth-Hitchcock Medical Center

    See if you can join NCT06134375 on ClinicalTrials.gov

17. This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

    This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Zumutor Biologics Inc.

    See if you can join NCT06451497 on ClinicalTrials.gov

18. Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

    This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant chemotherapy.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06435351 on ClinicalTrials.gov

19. A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

    The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    6 in total

    Run by

    Mabwell (Shanghai) Bioscience Co., Ltd.

    See if you can join NCT06908928 on ClinicalTrials.gov

20. Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

    To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06318897 on ClinicalTrials.gov

21. Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

    This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Hartford Healthcare, Hartford, Connecticut

    Locations

    12 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT03808337 on ClinicalTrials.gov

22. A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

    The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04683679 on ClinicalTrials.gov

23. Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

    The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) in people with triple negative (HER2 negative, hormone receptor negative) breast cancer undergoing breast conservation therapy.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Morton Plant Hospital - Baycare Health System, Clearwater, Florida

    Locations

    2 in total

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT05528133 on ClinicalTrials.gov

24. DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

    The purpose of the study is to find out if an investigational vaccine called Dendritic Cell (DC) vaccine given together with standard of care chemotherapy drugs can help people with Triple Negative and HR low positive breast cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT05504707 on ClinicalTrials.gov

25. A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

    The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Los Angeles Cancer Network (LACN) - Good Sam, Los Angeles, California

    Locations

    16 in total

    Run by

    Gilead Sciences

    See if you can join NCT06926920 on ClinicalTrials.gov